Treatment Outcome and Prognostic Factors in Male Patients with Stage IV Breast Cancer: A Population-Based Study.

Ying Huang,Wei Chen,Sean Szeja,Sandra S. Hatch,Andrew M. Farach,Darlene M. Miltenburg,E. Brian Butler,Bin S. Teh
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.572
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:572 Background: Stage IV male breast cancer (MBC) is a rare disease, previously described in small, single institutional studies. The purpose of this study is to investigate treatment outcome and prognostic factors in stage IV MBC. Methods: Patients with stage IV MBC diagnosed between 1988 and 2012 who did not receive radiation therapy as part of the first course of treatment were selected from the SEER database. Treatment outcome and prognostic factors for disease-specific survival (DSS) and overall survival (OS) were evaluated. Results: We identified 8292 MBC cases and included 394 patients with stage IV disease, who had the required treatment information. Median overall survival was 21 months. The 5-year DSS and OS for stage IV MBC patients were 38.3% and 21.1%, respectively. Of those with known progesterone receptor (PR) status, 68.6% were PR-positive (PR+), which was associated with better DSS (P = 0.003) and OS (P < 0.001). Of the 394 patients, 197 (50%) received surgery for the primary tumor and 197 (50%) did not. Those undergoing primary tumor surgery had longer median DSS than those who did not (36 months VS 21months; p < 0.001). Additional factors that correlated with prolonged DSS and OS were smaller tumor size (P = 0.005, P = 0.009) and younger age (P = 0.021, P = 0.001). Significant associations with race, year of diagnosis, ER status, HER2 status, use of radiation therapy to the primary tumor were not observed. In multivariate analysis, smaller tumor size (OR, 1.93; 95% CI, 1.2-3.104), PR+ positivity (OR, 1.665; 95%CI, 1.201-2.309), younger age (OR, 1.456; 95%CI, 1.053-2.014) and surgery for primary tumor (OR, 0.506; 95%CI, 0.368-0.695) were associated with longer DSS. Conclusions: Although stage IV MBC has poor DSS and OS, patients with PR-negative (PR-) disease, older age ( > 65 years), tumor size > 2cm or those did not undergo initial surgery for primary tumor had the worst prognosis. This is the largest study of stage IV MBC to date and these findings will help address some of the inconsistencies regarding this rare type of breast cancer.
What problem does this paper attempt to address?